Özdemir Ö, Arsoy HEM. Commentary on COVID-19-induced liver injury in various age and risk groups. World J Virol 2023; 12(1): 44-52 [PMID: 36743662 DOI: 10.5501/wjv.v12.i1.44]
Corresponding Author of This Article
Öner Özdemir, MD, Professor, Department of Pediatrics, Sakarya University, Medical Faculty, Şirinevler Mahallesi Adnan Menderes Caddesi No. 193 Adapazarı, Sakarya 54100, Türkiye. ozdemir_oner@hotmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Virol. Jan 25, 2023; 12(1): 44-52 Published online Jan 25, 2023. doi: 10.5501/wjv.v12.i1.44
Commentary on COVID-19-induced liver injury in various age and risk groups
Öner Özdemir, Hacer Efnan Melek Arsoy
Öner Özdemir, Hacer Efnan Melek Arsoy, Department of Pediatrics, Sakarya University, Medical Faculty, Sakarya 54100, Türkiye
Author contributions: Özdemir Ö and HE Melek Arsoy wrote the mini-review.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Öner Özdemir, MD, Professor, Department of Pediatrics, Sakarya University, Medical Faculty, Şirinevler Mahallesi Adnan Menderes Caddesi No. 193 Adapazarı, Sakarya 54100, Türkiye. ozdemir_oner@hotmail.com
Received: September 25, 2022 Peer-review started: September 25, 2022 First decision: November 5, 2022 Revised: November 15, 2022 Accepted: December 21, 2022 Article in press: December 21, 2022 Published online: January 25, 2023 Processing time: 114 Days and 15.4 Hours
Abstract
Towards the end of 2019, a new type of coronavirus, severe acute respiratory syndrome, emerged in the city of Wuhan in China's Hubei Province. The first occurrence was described as a case of pneumonia. Coronavirus disease 2019 (COVID-19) can progress primarily with symptoms varying from a mild upper respiratory tract infection to severe pneumonia, acute respiratory distress syndrome, and death. Determining the mechanisms of action of this virus, which can affect all systems including gastrointestinal, is vital for predicting the progression of the disease and managing its treatment. It is important to demonstrate the mechanisms of action of COVID-19 in patients without a previously known chronic or systemic disease. Although there is still no specific treatment for the virus, various algorithms have been created. As a result of the applied algorithms, the response to the treatment was satisfactory in some patients, while unexpected side effects occurred in some patients. It helps to clarify whether the unwanted effects that occur are due to the effect of the disease or the side effects of the drugs used in the treatment. There is currently increasing interest in COVID-19 interaction with liver tissue. Therefore, we would like to discuss the details of liver injury/dysfunction in the current literature.
Core Tip: Coronavirus disease 2019 (COVID-19) can progress primarily with symptoms ranging from a mild upper respiratory tract infection to severe pneumonia, hepatic injury, and even death. There is currently increasing interest in COVID-19 interaction with liver tissue. We would like to discuss the details of liver injury/dysfunction in COVID-19 in the current literature.
